National Psoriasis Foundation. Psoriasis statistics. https://www.psoriasis.org/psoriasis-statistics/. 2022. Accessed 23 July 2024.

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

Article  PubMed  Google Scholar 

Armstrong A, Bohannan B, Mburu S, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12(4):1055–64.

Article  PubMed  Google Scholar 

American Academy of Dermatology. Psoriasis treatment: biologics. 2022. https://www.aad.org/public/diseases/psoriasis/treatment/medications/biologics. Accessed 18 Dec 2024.

Blauvelt A, Noe MH. The best psoriasis medications emerge. JAMA Dermatol. 2024;160(1):99–100.

Article  PubMed  Google Scholar 

Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.

Article  PubMed  PubMed Central  Google Scholar 

Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–69.

Article  PubMed  PubMed Central  Google Scholar 

ILUMYA® (tildrakizumab-asmn) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2024.

ILUMETRI (tildrakizumab) [prescribing information]. Barcelona, Spain: Almirall, S.A.; 2023.

Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.

Article  CAS  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.

Article  PubMed  Google Scholar 

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.

Article  PubMed  PubMed Central  Google Scholar 

Cameron C, Hutton B, Druchok C, et al. Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. J Comp Eff Res. 2018;7(11):1037–51.

Article  PubMed  Google Scholar 

Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.

Article  PubMed  PubMed Central  Google Scholar 

Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7(4):247–52.

Article  Google Scholar 

Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol. 2002;64(4):583–639.

Article  Google Scholar 

Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity–subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618–40.

Article  PubMed  PubMed Central  Google Scholar 

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641–56.

Article  PubMed  PubMed Central  Google Scholar 

ClinicalTrials.gov identifier: NCT00585650. Updated May 18, 2023. https://clinicaltrials.gov/study/NCT00585650. Accessed 25 April 2025.

ClinicalTrials.gov identifier: NCT03897088. Updated May 31, 2023. https://clinicaltrials.gov/study/NCT03897088. Accessed 24 April 2025.

Network of Care. Efficacy study of CDP870 in subjects with chronic plaque psoriasis who are candidate for systemic therapy and/or phototherapy/photochemotherapy. https://aging.networkofcare.org/riverside/CommunityResources/ClinicalTrials/Detail/NCT00245765. Accessed 25 April 2025.

AlMutairi N, Eassa BI. A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis. Expert Opin Bio Ther. 2021;21(2):297–8.

Article  CAS  Google Scholar 

Armstrong AW, Villanueva Quintero DG, Echeverria CM, Gu Y, Karunaratne M, Reyes SO. Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab. Am J Clin Dermatol. 2016;17(6):691–9.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661–9.

Article  PubMed  Google Scholar 

Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.

Article  CAS  PubMed  Google Scholar 

Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942–54.

Article  CAS  PubMed  Google Scholar 

Augustin M, Gottlieb AB, Laws P, et al. Bimekizumab versus secukinumab in plaque psoriasis: higher efficacy translates into benefits in patient-perceived symptoms and health-related quality of life in the BE RADIANT multicenter, randomized, doubleblinded phase 3b trial. J Clin Aesthet Dermatol. 2022;15(4 Suppl 1):S23–4.

Google Scholar 

Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–61.

Article  CAS  PubMed  Google Scholar 

Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;7(1):86–92.

Article  Google Scholar 

Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35(1):135–42.

Article  CAS  PubMed  Google Scholar 

Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–74.

Article  CAS  PubMed  Google Scholar 

Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–8.

Article  CAS  PubMed  Google Scholar 

Bissonnette R, Harel F, Krueger JG, et al. TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol. 2017;137(8):1638–45.

Article  CAS  PubMed  Google Scholar 

Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033–42.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Thaci D, Papp KA, et al. Bimekizumab vs adalimumab in plaque psoriasis: higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial. J Am Acad Dermatol. 2021;85(3 Supplement):AB146.

Article  Google Scholar 

Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2085–93.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.

Article  CAS